NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...

A team has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Company has now raised $6 million since founding to advance mRNA-based therapeutics designed to turn tumor cells into immune-activating cells ...

NewLimit Raises $435M to advance longevity medicine trials, expand ageing research programmes and accelerate clinical growth.

Harvard Stem Cell Institute (HSCI) researchers, representing five Harvard departments and affiliated institutions as well as the Massachusetts Institute of Technology (MIT), have demonstrated that ...